重组人血管内皮抑制素联合吉西他滨和白介素-2治疗老年晚期肾癌的疗效观察  

Effect of recombinant human endostatin combined gemcitabine and interleukin-2 on elderly patients with advanced renal cell carcinoma

作　　者：周铭[1] 宫敬[1] 庄乾元[2] 杨钧显 陈磊 

机构地区：[1]武汉科技大学附属天佑医院,武汉430064 [2]华中科技大学同济医学院附属同济医院,武汉430030 [3]武汉市普仁医院,武汉430081

出　　处：《中南药学》2015年第3期313-316,共4页Central South Pharmacy

摘　　要：目的观察重组人血管内皮抑素(RHE)联合吉西他滨(G)和白介素-2(IL-2)治疗老年晚期肾癌的近期疗效及安全性。方法选择109例已经过病理学检查确诊为老年晚期肾癌患者作为研究对象,随机分为2组。观察组54例,采用RHE+G+IL-2治疗;对照组55例,采用G+IL-2化疗。3个周期后对所有患者行CT复查,比较2组患者近期疗效、生活质量和毒性反应评分差异。结果观察组和对照组的客观有效率(ORR)分别为75.93%(41/54)和58.18%(32/55)(P<0.05)、临床受益率(CBR)分别为96.30%(52/54)和81.82%(45/55)(P<0.05);QOL改善稳定率分别为96.30%(52/54)和90.91%(50/55)(P>0.05),2组生活质量评分差异无统计学意义(χ2=1.871,P>0.05)。2组患者均有不同程度的不良反应,观察组和对照组Ⅲ级以上毒性反应发生率分别为74.07%(40/54)和69.09%(38/55),差异无统计学意义(P>0.05)。结论 RHE+G+IL-2治疗老年晚期肾癌近期疗效明显提高,不良反应未见增加并且安全性好。Objective To investigate the short-term efficacy, toxicity and tolerance of recombinant human endostatin combined gemcitabine and interleukin-2 on elderly patients with advanced renal cell carcinoma. Methods Totally 109 elderly patients pathologically diagnozed with advanced renal cell carcinoma were selected and divided into 2 groups randomly： an observation group of 54 patients using RHE ＋ G ＋ IL-2 treatment and a control group of 55 patients using G ＋ IL-2 chemotherapy. After 3 periods of treatment all patients had CT examination, the shortterm efficacy, quality of life and toxicity reaction were compared in the 2 groups of patients. Results The objective response rate was 75.93%（41/54） in the observation group and 58.18%（32/55） in the control group respectively（P 0.05）. The clinical benefit rate was 96.30%（52/54） in the observation group and 81.82%（45/55） in the control group（P 0.05）. The rates of improved and stabled quality of life（QOL） was 96.30%（52/54） and 90.91%（50/55）（P 0.05） respectively. The difference in quality of life was not significant in both groups（χ2= 1.871, P 0.05）. The two groups of patients had different degrees of adverse reactions. Ⅲ magnitude toxicity reaction rates of the observation group and the control group were 74.07%（40/54） and 69.09%（38/55）, with no statistically significant difference（P 0.05）. Conclusion Recombinant human endostatin combined gemcitabine and interleukin-2 is effective for elderly patients with advanced renal cell carcinoma and can obviously increase the short-term curative effect, without increasing adverse reaction.

关 键 词：重组人血管内皮抑素 老年晚期肾癌 吉西他滨 白介素-2 

分 类 号：R969.4[医药卫生—药理学] R73[医药卫生—药学]